Drug intelligence / Profile preview

Liraglutide + Orlistat Combination

Development stage
Unknown
Lead developer
Novo Nordisk
Modality
Peptides, Small Molecules
Administration
Subcutaneous, Oral
01

Overview

This entry describes the potential concurrent use of two individual weight loss medications: liraglutide and orlistat. Liraglutide (brand names Saxenda, Victoza) is a GLP-1 receptor agonist that works by mimicking an intestinal hormone to increase feelings of fullness and decrease hunger signals[1][7]. Orlistat (brand names Xenical, Alli) is a lipase inhibitor that blocks the digestion and absorption of about one-third of dietary fat in the gut[1][5]. While each medication is FDA-approved for weight management and has demonstrated individual efficacy[2][3][7][8], the provided information does not detail specific clinical trials or official recommendations for their combined use[5]. Theoretically, their different mechanisms of action (appetite control vs. fat absorption inhibition) could be complementary[5]. However, concurrent use may amplify common gastrointestinal side effects associated with each drug, such as nausea, vomiting, diarrhea (liraglutide) and oily discharge, increased defecation, and fatty stools (orlistat)[1][5][7]. Orlistat use requires adherence to a low-fat diet to manage these side effects[5]. Any consideration of using these medications together would require careful medical supervision.

02

Targets

LIPF (Gastric lipase)GLP1R (GLP-1R)

Beyond the preview

Go deeper on Liraglutide + Orlistat Combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liraglutide + Orlistat Combination.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call